1-[(2-Methoxy-6-methyl-3-pyridinyl)methyl]-2-aziridinecarbonitril e

Ciamexon is a novel immunomodulator that has shown promising results in experimental models of autoimmune disease with little demonstrated cytotoxicity.Ciamexon can be used to study endocrine ophthalmopathies and diabetes mellitus, with slight improvement in ophthalmic disease following short-term administration.

Ciamexon on the development of diabetes in BB rats. Ciamexon was given once daily for 6 days per week beginning with the age of 42 or 50 days up to 120 days. For comparison, cyclosporin A (10 mg/kg) was applied following the same protocol. At 1 mg/kg, Ciamexon administration led to the complete prevention of diabetes in females but was not beneficial in males. At 10 mg/kg the drug caused significant suppression of diabetes development in males but more pronounced in females. Both, a reduction in the incidence of diabetes and a delay in the onset of hyperglycemia was observed only in females. After administration of cyclosporin A none of the animals developed diabetes. Ciamexon treatment did not affect granulocyte and lymphocyte counts and subsets in the peripheral blood except for a tendency to suppress eosinophilia. The growth of animals was not retarded. It is concluded that Ciamexon seems to influence the autoimmune state of the BB rat resulting in partial suppression of the disease.[1]

1. Kiesel U, et al. Suppression of spontaneous insulin-dependent diabetes in BB rats by administration of ciamexone. J Immunopharmacol. 1986;8(3):393-406.